SCV
SPRB

Sands Capital Ventures’s Spruce Biosciences SPRB Stock Holding History

Sands Capital Ventures’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,544
Closed -$301K – 22
2024
Q4 		$301K Sell
9,544
-949
-9% -$34.8K 0.07% 21
2024
Q3 		$370K Hold
10,493
– – 0.1% 14
2024
Q2 		$409K Hold
10,493
– – 0.14% 13
2024
Q1 		$622K Hold
10,493
– – 0.15% 13
2023
Q4 		$2.31M Hold
10,493
– – 0.64% 12
2023
Q3 		$1.78M Hold
10,493
– – 0.53% 14
2023
Q2 		$1.69M Hold
10,493
– – 0.5% 11
2023
Q1 		$1.74M Hold
10,493
– – 0.43% 14
2022
Q4 		$866K Hold
10,493
– – 0.24% 17
2022
Q3 		$1.08M Hold
10,493
– – 0.31% 17
2022
Q2 		$1.37M Hold
10,493
– – 0.38% 18
2022
Q1 		$1.58M Hold
10,493
– – 0.33% 17
2021
Q4 		$3.51M Hold
10,493
– – 0.52% 15
2021
Q3 		$4.73M Buy
+10,493
New +$6.59M 0.71% 12

Other funds holding SPRB

CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Ventures's SPRB Position: Q1 2025 in Review

Sands Capital Ventures sold out of Spruce Biosciences (SPRB) in Q1 2025, closing a stake of 9,544 shares — an estimated $301K sold.

Sands Capital Ventures first reported a position in SPRB in Q3 2021 and held it in 14 quarters. The position peaked at $4.73M in Q3 2021. 31 funds tracked by Wall St. Rank hold SPRB as of Q1 2025.

  • Sands Capital Ventures reported no remaining Spruce Biosciences position as of Q1 2025 after selling out during the quarter.
  • Sands Capital Ventures sold 9,544 Spruce Biosciences shares in Q1 2025, an estimated $301K.
  • Sands Capital Ventures first reported a position in Spruce Biosciences in Q3 2021 and held it in 14 quarters.
  • Sands Capital Ventures's Spruce Biosciences position peaked at $4.73M in Q3 2021.
  • 31 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2025.

Based on Sands Capital Ventures's 13F filing for Q1 2025, filed 14 May 2025.